Type I collagen matrix plus polyhexamethylene biguanide antimicrobial for the treatment of cutaneous wounds.
J Comp Eff Res
Aim: Determine the effectiveness of purified native type I collagen matrix plus polyhexamethylene biguanide antimicrobial (PCMP) on cutaneous wounds. Materials & methods: A prospective cohort study of 307 patients (67 venous leg ulcers, 62 diabetic foot ulcers, 45 pressure ulcers, 54 postsurgical wounds and 79 other wounds) was conducted. Results: Cox wound closure for PCMP was 73% at week 32. The median time to wound closure was 17 weeks (Kaplan-Meier). The incidence of PCMP-treated wounds showing >60% reductions in areas, depths and volumes were 81, 71 and 85%, respectively. Conclusion: PCMP demonstrated clinically meaningful benefits to patients with various types of cutaneous wounds. Clinical Trial registration number: NCT03286452.
Bain, Michael; Koullias, George J; Morse, Keith; Wendling, Santina; and Sabolinski, Michael L, "Type I collagen matrix plus polyhexamethylene biguanide antimicrobial for the treatment of cutaneous wounds." (2020). Articles, Abstracts, and Reports. 3285.